Insulet (NASDAQ: PODD) is a leading medical device company specializing in innovative tubeless insulin pump technology. Its flagship product, the Omnipod, provides a crucial alternative to traditional insulin injections, significantly improving diabetes management for patients. This advanced technology positions Insulet as a key innovator in the highly competitive diabetes care market.
On May 6, 2026, analyst firm Citigroup maintained a "Neutral" rating on Insulet stock, advising investors to hold rather than buy or sell. Citigroup also adjusted its price target for Insulet, lowering it from $230.00 to $175.00. At the time of the analyst report, Insulet's stock was trading at $150.09.
Despite the cautious analyst sentiment, Insulet reported robust first-quarter results. The company achieved earnings of $1.42 per share, surpassing the Zacks Consensus Estimate of $1.14 per share. This represents a significant increase from the $1.02 per share reported in the prior year's quarter, underscoring strong earnings growth.
Insulet's revenue also exceeded expectations, reaching $761.70 million, marking a substantial 33.90% increase year-over-year. As reported by Business Wire, this impressive revenue growth was primarily fueled by the success of its Omnipod brand. U.S. revenue expanded by 28.30% to $515.60 million, while international revenue surged by 59.40% to $242.90 million.
Following these positive results, Insulet raised its annual revenue forecast, as highlighted by Reuters. Despite the strong financial performance, the stock price experienced a recent decline of 10.17%, settling at $150.49. Over the past year, Insulet's stock has traded within a 52-week range from a low of $148.29 to a high of $354.88, with the company maintaining a market capitalization of $10.42 billion.
